Patents by Inventor Scott Jenkins

Scott Jenkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230248866
    Abstract: The invention describes a portable apparatus to treat surfaces and the air with hydroxyl ions to reduce the viability and/or kill pathogens.
    Type: Application
    Filed: February 9, 2023
    Publication date: August 10, 2023
    Inventors: Dustin Scott Jenkins, Christopher Martin Zazzetti, Robert Turner, Brian Williams, Madelynn Turner
  • Publication number: 20220136709
    Abstract: A cooking system (10) for a space restricted environment includes at least one cooking unit (12) having at least one cooking hob (11) movable between a stowed position and a deployed position such that in the stowed position the cooking hob (11) is located either behind or below an corresponding surface of a countertop (22), cabinet, wall or the like and in the deployed position the cooking hob (11) upwardly extends through an opening (28) in the corresponding surface
    Type: Application
    Filed: February 20, 2020
    Publication date: May 5, 2022
    Inventors: Kevin WOLTERINK, Martin JORDAN, Mohammad MUSAMEH, Simon Scott JENKINS, Victor HAANS, Yannick MAASKANT
  • Publication number: 20150216822
    Abstract: The invention is directed to compositions comprising stable nanoparticulate cinacalcet or a salt thereof. The composition can exhibit an improved dissolution rate, improved bioavailability, and reduced difference in absorption when administered orally under fed as compared to fasting conditions. The invention also encompasses methods of making and using such compositions.
    Type: Application
    Filed: April 17, 2015
    Publication date: August 6, 2015
    Applicant: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Deborah NEVILLE, Scott JENKINS, David MANSER
  • Patent number: 9012511
    Abstract: Described are compositions of stable nanoparticulate cinacalcet or a salt thereof, and methods of making and using them. The compositions exhibit an improved dissolution rate, improved bioavailability, and reduced difference in absorption when administered orally under fed as compared to fasting conditions.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: April 21, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Deborah Neville, Scott Jenkins, David Manser
  • Patent number: 8819020
    Abstract: A computer implemented method, apparatus, and computer usable program product for ranking and categorizing criminal offenders in a jurisdiction. In one embodiment, external data associated with the offenders is processed in a set of data models to generate a ranking index of criminal offenders. The external data comprises offender data elements related to prior arrests. The computer software and web application enables officers, detectives, and supervisors to research the offenders in their jurisdiction. They can intentionally track and monitor the status of the offenders that are not currently incarcerated. They can deliberately increase lawful contacts with these high-rate and treacherous offenders.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: August 26, 2014
    Inventors: Daniel Scott Jenkins, Brandon Matthew Rana
  • Patent number: 8367112
    Abstract: The present invention is directed to nanoparticulate carvedilol compositions having improved pharmacokinetic profiles, improved bioavailability, dissolution rates and efficacy. In one embodiment, the nanoparticulate carvedilol composition has an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: February 5, 2013
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Gary Liversidge, Scott Jenkins
  • Patent number: 8309133
    Abstract: The present invention is directed to nanoparticulate quinazoline derivative compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The nanoparticulate quinazoline derivative particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of hyperproliferative disorders, such as cancer and other neoplastic diseases. The compositions may include quinazolinamine derivatives such as erlotinib or a salt thereof.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: November 13, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Gary G. Liversidge, Scott Jenkins
  • Publication number: 20120278325
    Abstract: A computer implemented method, apparatus, and computer usable program product for ranking and categorizing criminal offenders in a jurisdiction. In one embodiment, external data associated with the offenders is processed in a set of data models to generate a ranking index of criminal offenders. The external data comprises offender data elements related to prior arrests. The computer software and web application enables officers, detectives, and supervisors to research the offenders in their jurisdiction. They can intentionally track and monitor the status of the offenders that are not currently incarcerated. They can deliberately increase lawful contacts with these high-rate and treacherous offenders.
    Type: Application
    Filed: April 27, 2012
    Publication date: November 1, 2012
    Inventors: Daniel Scott Jenkins, Brandon Matthew Rana
  • Publication number: 20120128780
    Abstract: Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal.
    Type: Application
    Filed: October 17, 2011
    Publication date: May 24, 2012
    Inventors: Gary G. Liversidge, Scott Jenkins
  • Publication number: 20120121653
    Abstract: The present invention is directed to mometasone furoate compositions comprising mometasone furoate and at least one surface stabilizer. The mometasone furoate particles of the composition preferably have an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: December 4, 2006
    Publication date: May 17, 2012
    Inventors: Scott Jenkins, Gary G. Liversidge
  • Patent number: 8158153
    Abstract: Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: April 17, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Gary G. Liversidge, Scott Jenkins
  • Publication number: 20120076863
    Abstract: The present invention is directed to anti-hypertensive compositions comprising a nanoparticulate temocapril, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate temocapril particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of hypertension and related diseases.
    Type: Application
    Filed: September 29, 2011
    Publication date: March 29, 2012
    Inventors: Scott Jenkins, Gary Liversidge
  • Publication number: 20120003319
    Abstract: The invention provides an oral formulation for administering to a subject comprising an imatinib compound and an enteric matrix or enteric coating or a combination thereof, whereby at least 80% of the imatinib compound is released in the small intestine of the subject. Methods of using such formulation is also provided.
    Type: Application
    Filed: March 19, 2009
    Publication date: January 5, 2012
    Applicant: ELAN PHARMA INTERNATIONAL LIMITED
    Inventors: Gary Liversidge, Scott Jenkins
  • Publication number: 20110287065
    Abstract: The invention is directed to compositions comprising stable nanoparticulate cinacalcet or a salt thereof. The composition can exhibit an improved dissolution rate, improved bioavailability, and reduced difference in absorption when administered orally under fed as compared to fasting conditions. The invention also encompasses methods of making and using such compositions.
    Type: Application
    Filed: May 18, 2011
    Publication date: November 24, 2011
    Inventors: Deborah Neville, Scott Jenkins, David Manser
  • Patent number: 8003127
    Abstract: Compositions comprising a nanoparticulate corticosteroid and an antihistamine are described. The compositions are useful in the prophylaxis and chronic treatment of asthma in adults and pediatric patients and for the relief of allergic conjunctivitis, symptoms of seasonal allergic rhinitis in adults and pediatric patients. Combining an antihistamine with a nanoparticulate corticosteroid in a single formulation results in improved efficacy.
    Type: Grant
    Filed: March 23, 2006
    Date of Patent: August 23, 2011
    Assignee: Elan Pharma International Limited
    Inventors: Gary Liversidge, Scott Jenkins, H. William Bosch, Christian F. Wertz
  • Publication number: 20110195095
    Abstract: Described are injectable formulations of nanoparticulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise nanoparticulate olanzapine.
    Type: Application
    Filed: February 9, 2011
    Publication date: August 11, 2011
    Inventors: Gary Liversidge, Scott Jenkins, Elaine Merisko Liversidge
  • Publication number: 20110159054
    Abstract: The present invention is directed to compositions comprising an acylanilide, such as bicalutamide, having improved solubility in water. The bicalutamide particles of the composition have an effective average particle size of less than about 2000 nm, and are useful in the treatment of prostate cancer.
    Type: Application
    Filed: March 2, 2011
    Publication date: June 30, 2011
    Inventors: Scott Jenkins, Gary Liversidge
  • Patent number: 7910577
    Abstract: Described are injectable formulations of nanoparticulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise nanoparticulate olanzapine.
    Type: Grant
    Filed: November 16, 2005
    Date of Patent: March 22, 2011
    Assignee: Elan Pharma International Limited
    Inventors: Gary Liversidge, Scott Jenkins, Elaine Merisko Liversidge
  • Publication number: 20110064803
    Abstract: The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of osteoporosis. The invention also relates to a controlled release composition comprising a vitamin K2 or a nanoparticulate vitamin K2 that in operation delivers the drug in a pulsed or multi-modal manner for the prevention and treatment of osteoporosis.
    Type: Application
    Filed: May 9, 2006
    Publication date: March 17, 2011
    Applicant: ELAN PHARMA INTERNATIONAL LIMITED.
    Inventors: John G. Devane, Paul Stark, Niall M.N. Fanning, Gurvinder Singh Rekhi, Gary Liversidge, Scott Jenkins
  • Publication number: 20100221327
    Abstract: The present invention is directed to compositions comprising a nanoparticulate azelnidipine, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate azelnidipine particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of hypertension and related diseases.
    Type: Application
    Filed: June 14, 2006
    Publication date: September 2, 2010
    Inventors: Scott Jenkins, Gary G. Liversidge